Humanigen Inc (OTCMKTS:HGEN) major shareholder Dale Chappell bought 32,028,669 shares of the stock in a transaction dated Tuesday, February 27th. The shares were bought at an average price of $0.09 per share, for a total transaction of $2,882,580.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Humanigen Inc (OTCMKTS HGEN) traded up $0.04 during trading on Thursday, hitting $0.65. The stock had a trading volume of 6,185 shares, compared to its average volume of 15,274. Humanigen Inc has a fifty-two week low of $0.13 and a fifty-two week high of $3.00. The company has a debt-to-equity ratio of -0.06, a quick ratio of 0.10 and a current ratio of 0.10.
TRADEMARK VIOLATION WARNING: “Insider Buying: Humanigen Inc (HGEN) Major Shareholder Acquires 32,028,669 Shares of Stock” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3231700/insider-buying-humanigen-inc-hgen-major-shareholder-acquires-32028669-shares-of-stock.html.
Humanigen, Inc, formerly KaloBios Pharmaceuticals, Inc, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.